Edwards Lifesciences Corporation Insider Trading

Last 12 months

Insiders sold $27.7M and bought nothing on the open market.

52% of the selling was scheduled in advance under 10b5-1 plans. CVP, TMTT, Surgical & IHFM Daveen Chopra sold $2.89M on Aug 26, 42% of their stake, outside a plan. The last open-market buy by an executive or director was in May 2024.

Net open-market

−$27.7M

0 buys · 41 sales

Under a 10b5-1 plan

52%

of the value sold

Insiders who bought / sold

0 / 9

executives and directors

Last open-market buy

May 2024

May 6, 2024

Get an email when EW's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 8	Daniel J. Lippis Cvp, Tavr	Sold10b5-1 plan	619	$85.65	53K	1.5%	Form 4
Sep 11	Daniel J. Lippis Cvp, Tavr	Sold10b5-1 plan	619	$87.51	54K	1.5%	Form 4
Aug 31	Andrew M. Dahl SVP, Corporate Controller	SoldNo plan	544	$91.06	50K	3.5%	Form 4
Aug 28	Annette Bruls Cvp, Emeacla	SoldNo plan	2,644	$89.98	238K	13%	Form 4
Aug 26	Daveen Chopra CVP, TMTT, Surgical & IHFM	SoldNo plan 2 parts	31,800	$91.02 average	$2.89M	42%	Form 4
Aug 26	Wayne Markowitz Cvp, Japac	SoldNo plan	1,240	$91.47	113K	5.8%	Form 4
Aug 11	Daniel J. Lippis Cvp, Tavr	Sold10b5-1 plan	619	$92.03	57K	1.5%	Form 4
Jul 30	Wayne Markowitz Cvp, Japac	SoldNo plan	146	$86.03	13K	0.7%	Form 4
Jul 28	Wayne Markowitz Cvp, Japac	SoldNo plan	9,628	$85.06	819K	31%	Form 4
Jul 27	Bernard J Zovighian CEO	SoldNo plan	2,921	$83.93	245K	2.3%	Form 4
Jul 10	Daniel J. Lippis Cvp, Tavr	Sold10b5-1 plan	619	$91.70	57K	1.5%	Form 4
Jun 30	Daniel J. Lippis Cvp, Tavr	Sold10b5-1 plan	619	$91.40	57K	1.5%	Form 4
Jun 17	Bernard J Zovighian CEO	Sold10b5-1 plan	523	$87.92	46K	0.5%	Form 4
May 29	Andrew M. Dahl SVP, Corporate Controller	SoldNo plan	568	$86.08	49K	3.6%	Form 4
May 27	Donald E Bobo Jr CVP,Strategy/Corp Development	SoldNo plan	23,145	$86.42	$2M	13%	Form 4
May 22	Daveen Chopra CVP, TMTT & Surgical	SoldNo plan	1,500	$84.60	127K	3.3%	Form 4
May 18	Daniel J. Lippis Cvp, Tavr	Sold10b5-1 plan	620	$81.14	50K	1.5%	Form 4
May 15	Donald E Bobo Jr CVP,Strategy/Corp Development	SoldNo plan 2 parts	17,968	$81.96 average	$1.47M	9.3%	Form 4
May 12	Bernard J Zovighian CEO	Sold10b5-1 plan 2 parts	36,351	$77.93 average	$2.83M	24%	Form 4
May 11	Wayne Markowitz Cvp, Japac	SoldNo plan	593	$79.73	47K	2.7%	Form 4
May 1 – 4	Daniel J. Lippis Cvp, Tavr	Sold10b5-1 plan 3 parts	2,038	$83.49 average	170K	5.7%	Form 4
Apr 9	Scott B. Ullem CVP, Chief Financial Officer	Sold10b5-1 plan 2 parts	13,000	$80.05 average	$1.04M	4.1%	Form 4
Apr 6	Daniel J. Lippis Cvp, Tavr	Sold10b5-1 plan	1,019	$80.98	83K	2.9%	Form 4
Apr 2	Donald E Bobo Jr CVP,Strategy/Corp Development	Sold10b5-1 plan 2 parts	22,680	$80.16 average	$1.82M	11%	Form 4
Mar 11	Scott B. Ullem CVP, Chief Financial Officer	Sold10b5-1 plan 2 parts	13,000	$84.92 average	$1.1M	4.1%	Form 4
Mar 11	Daniel J. Lippis Cvp, Tavr	Sold10b5-1 plan	1,019	$85.38	87K	2.9%	Form 4
Mar 2	Donald E Bobo Jr CVP,Strategy/Corp Development	Sold10b5-1 plan	11,340	$85.93	974K	5.9%	Form 4
Feb 25	Donald E Bobo Jr CVP,Strategy/Corp Development	SoldNo plan	24,000	$83.84	$2.01M	12%	Form 4
Feb 12	Bernard J Zovighian CEO	SoldNo plan 2 parts	22,430	$76.67 average	$1.72M	19%	Form 4
Jan 9	Daniel J. Lippis Cvp, Tavr	Sold10b5-1 plan	1,019	$85.70	87K	4.4%	Form 4
Jan 6	Donald E Bobo Jr CVP,Strategy/Corp Development	Sold10b5-1 plan 2 parts	11,340	$85.66 average	971K	5.2%	Form 4
Dec 12, 2025	Donald E Bobo Jr CVP,Strategy/Corp Development	SoldNo plan 2 parts	11,386	$83.76 average	954K	5.2%	Form 4
Dec 12, 2025	Daniel J. Lippis Cvp, Japac	Sold10b5-1 plan	1,019	$84.03	86K	4.4%	Form 4
Dec 12, 2025	Heisz Leslie Stone Director	SoldNo plan	2,615	$83.41	218K	7.8%	Form 4
Dec 11, 2025	Daveen Chopra CVP, TMTT & Surgical	SoldNo plan	2,000	$84.38	169K	5.8%	Form 4
Dec 10, 2025	Donald E Bobo Jr CVP,Strategy/Corp Development	Sold10b5-1 plan	11,340	$83.83	951K	4.8%	Form 4
Dec 8, 2025 – Dec 10, 2025	Bernard J Zovighian CEO	Sold10b5-1 plan 2 parts	25,350	$84.94 average	$2.15M	21%	Form 4
Dec 9, 2025	Scott B. Ullem CVP, Chief Financial Officer	Sold10b5-1 plan	7,700	$84.47	650K	2.5%	Form 4
Dec 8, 2025	Wayne Markowitz Cvp, Japac	SoldNo plan	583	$86.01	50K	3.2%	Form 4
Nov 10, 2025	Scott B. Ullem CVP, Chief Financial Officer	Sold10b5-1 plan 2 parts	13,000	$83.08 average	$1.08M	4.1%	Form 4

Oct 810b5-1 plan
Daniel J. Lippis
Cvp, Tavr · sold 619 at $85.65
53K
1.5% of stake
Sep 1110b5-1 plan
Daniel J. Lippis
Cvp, Tavr · sold 619 at $87.51
54K
1.5% of stake
Aug 31No plan
Andrew M. Dahl
SVP, Corporate Controller · sold 544 at $91.06
50K
3.5% of stake
Aug 28No plan
Annette Bruls
Cvp, Emeacla · sold 2,644 at $89.98
238K
13% of stake
Aug 26No plan
Daveen Chopra
CVP, TMTT, Surgical & IHFM · sold 31,800 at avg $91.02
$2.89M
42% of stake
Aug 26No plan
Wayne Markowitz
Cvp, Japac · sold 1,240 at $91.47
113K
5.8% of stake
Aug 1110b5-1 plan
Daniel J. Lippis
Cvp, Tavr · sold 619 at $92.03
57K
1.5% of stake
Jul 30No plan
Wayne Markowitz
Cvp, Japac · sold 146 at $86.03
13K
0.7% of stake
Jul 28No plan
Wayne Markowitz
Cvp, Japac · sold 9,628 at $85.06
819K
31% of stake
Jul 27No plan
Bernard J Zovighian
CEO · sold 2,921 at $83.93
245K
2.3% of stake
Jul 1010b5-1 plan
Daniel J. Lippis
Cvp, Tavr · sold 619 at $91.70
57K
1.5% of stake
Jun 3010b5-1 plan
Daniel J. Lippis
Cvp, Tavr · sold 619 at $91.40
57K
1.5% of stake
Jun 1710b5-1 plan
Bernard J Zovighian
CEO · sold 523 at $87.92
46K
0.5% of stake
May 29No plan
Andrew M. Dahl
SVP, Corporate Controller · sold 568 at $86.08
49K
3.6% of stake
May 27No plan
Donald E Bobo Jr
CVP,Strategy/Corp Development · sold 23,145 at $86.42
$2M
13% of stake
May 22No plan
Daveen Chopra
CVP, TMTT & Surgical · sold 1,500 at $84.60
127K
3.3% of stake
May 1810b5-1 plan
Daniel J. Lippis
Cvp, Tavr · sold 620 at $81.14
50K
1.5% of stake
May 15No plan
Donald E Bobo Jr
CVP,Strategy/Corp Development · sold 17,968 at avg $81.96
$1.47M
9.3% of stake
May 1210b5-1 plan
Bernard J Zovighian
CEO · sold 36,351 at avg $77.93
$2.83M
24% of stake
May 11No plan
Wayne Markowitz
Cvp, Japac · sold 593 at $79.73
47K
2.7% of stake
May 1 – 410b5-1 plan
Daniel J. Lippis
Cvp, Tavr · sold 2,038 at avg $83.49
170K
5.7% of stake
Apr 910b5-1 plan
Scott B. Ullem
CVP, Chief Financial Officer · sold 13,000 at avg $80.05
$1.04M
4.1% of stake
Apr 610b5-1 plan
Daniel J. Lippis
Cvp, Tavr · sold 1,019 at $80.98
83K
2.9% of stake
Apr 210b5-1 plan
Donald E Bobo Jr
CVP,Strategy/Corp Development · sold 22,680 at avg $80.16
$1.82M
11% of stake
Mar 1110b5-1 plan
Scott B. Ullem
CVP, Chief Financial Officer · sold 13,000 at avg $84.92
$1.1M
4.1% of stake
Mar 1110b5-1 plan
Daniel J. Lippis
Cvp, Tavr · sold 1,019 at $85.38
87K
2.9% of stake
Mar 210b5-1 plan
Donald E Bobo Jr
CVP,Strategy/Corp Development · sold 11,340 at $85.93
974K
5.9% of stake
Feb 25No plan
Donald E Bobo Jr
CVP,Strategy/Corp Development · sold 24,000 at $83.84
$2.01M
12% of stake
Feb 12No plan
Bernard J Zovighian
CEO · sold 22,430 at avg $76.67
$1.72M
19% of stake
Jan 910b5-1 plan
Daniel J. Lippis
Cvp, Tavr · sold 1,019 at $85.70
87K
4.4% of stake
Jan 610b5-1 plan
Donald E Bobo Jr
CVP,Strategy/Corp Development · sold 11,340 at avg $85.66
971K
5.2% of stake
Dec 12, 2025No plan
Donald E Bobo Jr
CVP,Strategy/Corp Development · sold 11,386 at avg $83.76
954K
5.2% of stake
Dec 12, 202510b5-1 plan
Daniel J. Lippis
Cvp, Japac · sold 1,019 at $84.03
86K
4.4% of stake
Dec 12, 2025No plan
Heisz Leslie Stone
Director · sold 2,615 at $83.41
218K
7.8% of stake
Dec 11, 2025No plan
Daveen Chopra
CVP, TMTT & Surgical · sold 2,000 at $84.38
169K
5.8% of stake
Dec 10, 202510b5-1 plan
Donald E Bobo Jr
CVP,Strategy/Corp Development · sold 11,340 at $83.83
951K
4.8% of stake
Dec 8, 2025 – Dec 10, 202510b5-1 plan
Bernard J Zovighian
CEO · sold 25,350 at avg $84.94
$2.15M
21% of stake
Dec 9, 202510b5-1 plan
Scott B. Ullem
CVP, Chief Financial Officer · sold 7,700 at $84.47
650K
2.5% of stake
Dec 8, 2025No plan
Wayne Markowitz
Cvp, Japac · sold 583 at $86.01
50K
3.2% of stake
Nov 10, 202510b5-1 plan
Scott B. Ullem
CVP, Chief Financial Officer · sold 13,000 at avg $83.08
$1.08M
4.1% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch EW, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Orthopedic, Prosthetic & Surgical Appliances & Supplies · Pick stocks to compare with EW

CompareIntrinsic value

STESTERIS plc

$247.91+7.16%70

ZBHZimmer Biomet Holdings, Inc.

$110.15+13.49%66

ALGNAlign Technology, Inc.

$164.90+8.79%66

ENOVEnovis Corporation

$24.42+16.90%42

ISRGIntuitive Surgical Inc.

$482.10+9.38%83

MSAMsa Safety Inc.

$177.60+2.03%75

AVNSAvanos Medical Inc.

No recent price12

RMDResMed Inc.

$240.51+5.91%91

Held by ETFs

EW is in 288 US ETFs. The largest of them, with EW's weight in each:

Spot a number that looks wrong? Check it in EW's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing EW

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.